NEW YORK--(BUSINESS WIRE)--Jan. 28, 2019--
UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical
company developing treatments to address unmet needs in the field of
urology, with a focus on uro-oncology, today announced the closing of
its previously announced public offering of 4,207,317 ordinary shares,
including 548,780 shares sold pursuant to the full exercise of the
underwriters’ option to purchase additional shares. All of the ordinary
shares were sold at a price to the public of $41.00 per share. The net
proceeds of the public offering are approximately $162.1 million, after
deducting the underwriting discounts and commissions but before payment
of other offering expenses. All ordinary shares sold in the offering
were offered by the Company.
Goldman Sachs & Co. LLC, J.P. Morgan and Jefferies acted as joint
book-running managers for the offering. Oppenheimer & Co. acted as lead
manager for the offering.
A shelf registration statement relating to the ordinary shares was
previously filed with the Securities and Exchange Commission (the “SEC”)
and declared effective on October 26, 2018. A final prospectus
supplement and accompanying prospectus relating to the offering was
filed with the SEC and is available on the SEC’s website at http://www.sec.gov.
Copies of the final prospectus supplement and accompanying prospectus
may be obtained by contacting:
- Goldman Sachs & Co. LLC, c/o: Prospectus Department, 200 West Street,
New York, New York 10282, or via telephone at 866-471-2526, or via
email: prospectus-ny@ny.email.gs.com;
or
- J.P. Morgan Securities LLC, c/o: Broadridge Financial Solutions, 1155
Long Island Avenue, Edgewood, New York 11717 or via telephone at
866-803-9204, or via email: prospectus-eq_fi@jpmorgan.com;
or
- Jefferies LLC, c/o: Equity Syndicate Prospectus Departments, 520
Madison Avenue, 2nd Floor, New York, New York 10022, or via telephone
at 877-821-7388, or via email: prospectus_department@jefferies.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there be any
sale of these securities in any state or other jurisdiction in which
such offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state or other
jurisdiction.
About UroGen Pharma Ltd.
UroGen Pharma Ltd. (Nasdaq:URGN) is a clinical-stage biopharmaceutical
company developing advanced non-surgical treatments to address unmet
needs in the field of urology, with a focus on uro-oncology. UroGen has
developed RTGel™, a proprietary sustained release, hydrogel-based
platform technology that has the potential to improve therapeutic
profiles of existing drugs. UroGen’s sustained release technology is
designed to enable longer exposure of the urinary tract tissue to
medications, making local therapy a potentially more effective treatment
option. UroGen’s lead product candidates, UGN-101 and UGN-102, are
designed to potentially remove tumors by non-surgical means and to treat
several forms of non-muscle invasive urothelial cancer, including
low-grade upper tract urothelial carcinoma and bladder cancer,
respectively. UroGen is headquartered in New York, NY with operations in
Los Angeles, CA and Israel.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190128005529/en/
Source: UroGen Pharma Ltd.
UROGEN
Kate Bechtold
Director, Corporate Communications
& Investor Relations
Kate.Bechtold@urogen.com
914-552-0456
